HighTower Advisors’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$50.1K Buy
54,491
+1,700
+3% +$2.06K ﹤0.01% 3707
2025
Q4
$67.6K Hold
52,791
﹤0.01% 3553
2025
Q3
$68.6K Sell
52,791
-171,422
-76% -$225K ﹤0.01% 3587
2025
Q2
$269K Buy
224,213
+121,422
+118% +$135K ﹤0.01% 3029
2025
Q1
$111K Buy
102,791
+10,000
+11% +$14K ﹤0.01% 3339
2024
Q4
$162K Buy
92,791
+10,690
+13% +$19.9K ﹤0.01% 3257
2024
Q3
$160K Sell
82,101
-6,000
-7% -$11.8K ﹤0.01% 3203
2024
Q2
$157K Buy
88,101
+12,000
+16% +$29.3K ﹤0.01% 3095
2024
Q1
$206K Sell
76,101
-116,569
-61% -$281K ﹤0.01% 2965
2023
Q4
$426K Hold
192,670
﹤0.01% 2436
2023
Q3
$559K Sell
192,670
-593,616
-75% -$1.55M ﹤0.01% 2159
2023
Q2
$1.52M Sell
786,286
-206,233
-21% -$407K ﹤0.01% 1513
2023
Q1
$1.94M Buy
992,519
+536,341
+118% +$1.06M ﹤0.01% 1302
2022
Q4
$534K Buy
456,178
+208,931
+85% +$257K ﹤0.01% 2092
2022
Q3
$272K Sell
247,247
-88,824
-26% -$134K ﹤0.01% 2408
2022
Q2
$538K Buy
336,071
+145,683
+77% +$360K ﹤0.01% 2005
2022
Q1
$683K Sell
190,388
-1,242
-0.6% -$4.29K ﹤0.01% 1978
2021
Q4
$751K Buy
+191,630
New +$897K ﹤0.01% 1919

Other funds holding LAB

HighTower Advisors's LAB Position: Q1 2026 in Review

HighTower Advisors increased its Standard BioTools (LAB) stake by 3.2% in Q1 2026, buying an estimated $2.06K and bringing the position to 54,491 shares worth $50.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3707.

HighTower Advisors first reported a position in LAB in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.94M in Q1 2023. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • HighTower Advisors held 54,491 shares of Standard BioTools worth $50.1K as of Q1 2026.
  • HighTower Advisors bought 1,700 Standard BioTools shares in Q1 2026, an estimated $2.06K.
  • Standard BioTools made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3707 holding.
  • HighTower Advisors first reported a position in Standard BioTools in Q4 2021 and has held it in 18 quarters since.
  • HighTower Advisors's Standard BioTools position peaked at $1.94M in Q1 2023.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.